Validation of Stability Indicating HPLC Method in the Application of Comparative Pharmacokinetic Studies of Atorvastatin in Different Pharmaceutical Formulations (bulk drug, tablet, and nanoemulsion).

Authors

  • Gulam Mustafa Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi-62, INDIA
  • Mohd Aamir Mirza Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi-62, INDIA
  • Zeenat Iqbal Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi-62, INDIA
  • Sushama Talegaonkar Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi-62, INDIA

Abstract

A simple, highly sensitive, isocratic stability indicating reversed phase-high performance liquid chromatography (RP-HPLC) method with UV detection at 247 nm was developed and validated for analysis of Atorvastatin (AT). Diclofenac was used as an internal standard (IS). Retention times of the AT and diclofenac (IS) were found to be 4.2 and 8.2 min, respectively. A mobile phase consisting of 0.05 M sodium phosphate buffer and methanol (30:70 v/v) pH 4.1 at flow rate 1ml/min was employed in this study. The calibration curves were linear with regression coefficient (r²) of 0.9997 ± 0.0014. The limits of detection (LOD) and the limits of quantitation (LOQ) were found out to be 5.0 and 15 ng/ml, respectively. The method was statistically validated in accordance with International Conference on Harmonization (ICH) guidelines. The proposed method is sensitive, specific and was successfully applied for the estimation of atorvastatin in pharmaceutical formulations (bulk drug, tablet, nanoemulsion) and in rat serum pharmacokinetic studies.

Keywords:

Chromatography, Atorvastatin, Nanoemulsion, Serum, Pharmacokinetics

References

1. A. P. Lea, D. M. Tavish, Drugs, 1997, 53:828-847

2. T. Bansal, G. Mustafa, Z. I. Khan, F. J. Ahmad, R. K. Khar, S. Talegaonkar, Crit Rev Ther Drug Carrier Syst, 2008, 25:63-116

3. V. Borek-Dohalsky, J. Huclova, B. Barrett, B. Nemec, I. Ulc, I. Jelinek, Anal Bioanal Chem, 2006, 386:275-285

4. W. W. Bullen, Miller RA, Hayes RN (1999) J Am Soc Mass Spectrom 10:55-66

5. M. Hermann, H. Christensen, J. L. Reubsaet, Anal Bioanal Chem, 2005, 382:1242-1249

6. M. Jemal, Z. Ouyang, B. C. Chen, D. Teitz, Rapid Commun Mass Spectrom, 1999, 13:1003-1015

7. R. Nirogi, K. Mudigonda, V. Kandikere, J Pharm Biomed Anal, 2007, 44:379-387

8. R. P. Shah, V. Kumar, S. Singh, Rapid Commun Mass Spectrom, 2008, 22:613-622

9. G. Bahrami, B. Mohammadi, S. Mirzaeei, A. Kiani, J Chromatogr B Analyt Technol Biomed Life Sci, 2005, 826:41-45

10. H. R. Shen, Z. D. Li, M. K. Zhong, Pharmazie, 2006, 61:18-20

11. A. Zarghi, A. Shafaati, S. M. Foroutan, A. Khoddam, Arzneimittelforschung, 2005, 55:451-454

12. B. G. Chaudhari, N. M. Patel, P. B. Shah, Chem Pharm Bull, 2007, 55:241-246

13. S. Erturk, A. E. Sevinc, L. Ersoy, S. Ficicioglu, J Pharm Biomed Anal, 2003, 33:1017-1023

14. A. Mohammadi, N. Rezanour, D. M. Ansari, B. F. Ghorbani, M. Hashem, R. B. Walker, J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 846: 215-221

15. M. K. Pasha, S. Muzeeb, S. J. Basha, D. Shashikumar, R. Mullangi, N. R. Srinivas, Biomed Chromatogr, 2006, 20:282-293

16. B. Stanisz, L. Kania, Acta Pol Pharm, 2006, 63:471-476

17. International Conference on Harmonization (ICH) of technical requirements for registration of pharmaceuticals for human use: Harmonized Triplicate Guideline on Validation of Analytical

18. M. Zaxariou, I. Panderi, J Pharm Biomed Anal, 2004, 35:41-50

19. H. R. Shen, M. K. Zhong, J Pharm Pharmacol, 2006, 58:1183-1191

Published

2025-01-01
Statistics
Abstract Display: 6
PDF Downloads: 0

Issue

Vol. 1 No. 1 (2009): Volume 1,Issue1

Section

Articles